TrialCancer medicine2024

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy.

Yuguang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.